Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
Psyence BioMed (Nasdaq: PBM) adjourned its annual and special shareholder meeting scheduled for January 22, 2026 to February 12, 2026 at 9:00 a.m. New York Time / 4:00 p.m. Cape Town Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Psyence BioMed (Nasdaq: PBM) adjourned its annual and special shareholder meeting scheduled for January 22, 2026 to February 12, 2026 at 9:00 a.m. New York Time / 4:00 p.m. Cape Town Time. The reconvened Meeting will be held at Venture Workspace Riverlands, Office Building 4, Riverlands, 51 Gogosoa Street, Observatory, Cape Town, 7935, South Africa.
The adjournment occurred because the requisite shareholder quorum was not achieved. The company is working with its proxy agents to help obtain quorum for the February 12, 2026 meeting. The record date remains close of business on December 23, 2025. For details of the Meeting business, see the company notice of meeting and management information circular dated January 2, 2026, filed on EDGAR.
Details
News Market Reaction – PBM
On Jan 22, the day this news came out, PBM closed 12.69% below the previous close.
Data tracked by StockTitan Argus for the Jan 22 session.
Key Figures
- Original meeting date
- January 22, 2026
- Initial annual and special shareholder meeting date
- Adjourned meeting date
- February 12, 2026
- New date for reconvened shareholder meeting
- Meeting time NY
- 9:00 a.m.
- New York time for reconvened meeting
- Meeting time Cape Town
- 4:00 p.m.
- Cape Town time for reconvened meeting
- Record date
- December 23, 2025
- Record date for determining shareholders entitled to vote
- Price change 24h
- -79.2%
- Move prior to this meeting adjournment announcement
- 52-week high
- $108.5913
- Pre-news 52-week high level
- 52-week low
- $0.64
- Pre-news 52-week low level
Historical Context
-
Postponement of previously announced 1-for-6.25 reverse stock split effective date.
-
Board sets effective date and mechanics for 1-for-6.25 reverse stock split.
-
Board approves 2026 financial strategy and potential share repurchase program.
-
Milestone in GMP ibogaine HCl production and disclosure of cash and trial status.
-
Ethics approval to use PsyLabs’ psilocybin product in Phase IIb trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
quorum regulatory
proxy agents regulatory
management information circular regulatory
record date regulatory
EDGAR regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that it adjourned its annual and special meeting of shareholders (the “Meeting”) until February 12, 2026.
The Meeting will now be held on February 12, 2026, at 9:00 a.m. New York Time/4:00 p.m. Cape Town time at Venture Workspace Riverlands, Office Building 4, Riverlands, 51 Gogosoa Street, Observatory, Cape Town, 7935, South Africa.
The adjournment is a result of the requisite quorum of shareholders not having been achieved to hold the Meeting. The Company is working with its proxy agents to help ensure that quorum is obtained for the reconvened meeting on February 12, 2026. For details concerning the business of the Meeting, please see the Company’s notice of meeting and management information circular dated January 2, 2026, filed on EDGAR. Please note that the record date for the Meeting, close of business on December 23, 2025, has not changed.
About Psyence BioMed
Psyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.
Contact Information for Psyence Biomedical Ltd.
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Investor Contact:
Michael Kydd
Investor Relations Advisor
michael@psyencebiomed.com
Forward Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.
Forward-looking statements in this communication include statements regarding the reconvening of the Meeting and the timing (if any) of the Meeting. These statements are based on current assumptions and expectations, including that the Company will succeed in obtaining quorum for the reconvened Meeting. These assumptions may prove incorrect. There can be no assurance that the Company will be able to obtain quorum at the reconvened Meeting. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.
These risks and uncertainties include, among other difficulties, delays or challenges in obtaining quorum for the Meeting, including the possibility of claims or proceedings challenging the validity of quorum for the Meeting or the Meeting itself. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.
These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.
The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company’s product candidates are investigational and have not been approved by any regulatory authority for use in the treatment of any disease or condition, and clinical results (if any) may not be indicative of future results. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.